Brooklyn Cash per Share

BTX
 Stock
  

USD 0.25  0.01  4.17%   

Brooklyn Immunotherapeutics fundamentals help investors to digest information that contributes to Brooklyn Immunotherapeuti's financial success or failures. It also enables traders to predict the movement of Brooklyn Stock. The fundamental analysis module provides a way to measure Brooklyn Immunotherapeuti's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Brooklyn Immunotherapeuti stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  

Brooklyn Cash per Share Analysis

Brooklyn Immunotherapeuti's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Cash per Share 
 = 
Total Cash 
Average Shares 
More About Cash per Share | All Equity Analysis

Current Brooklyn Immunotherapeuti Cash per Share

    
  0.41 X  
Most of Brooklyn Immunotherapeuti's fundamental indicators, such as Cash per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Brooklyn Immunotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Compare to competition

In accordance with the recently published financial statements, Brooklyn Immunotherapeutics has a Cash per Share of 0.41 times. This is 90.57% lower than that of the Healthcare sector and 90.53% lower than that of the Biotechnology industry. The cash per share for all United States stocks is 91.82% higher than that of the company.

Brooklyn Cash per Share Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Brooklyn Immunotherapeuti's direct or indirect competition against its Cash per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Brooklyn Immunotherapeuti could also be used in its relative valuation, which is a method of valuing Brooklyn Immunotherapeuti by comparing valuation metrics of similar companies.
Brooklyn Immunotherapeuti is currently under evaluation in cash per share category among related companies.

Brooklyn Fundamentals

About Brooklyn Immunotherapeuti Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Brooklyn Immunotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Brooklyn Immunotherapeuti using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Brooklyn Immunotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Brooklyn Immunotherapeuti without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Volatility Analysis Now

   

Volatility Analysis

Get historical volatility and risk analysis based on latest market data
All  Next Launch Module

Pair Trading with Brooklyn Immunotherapeuti

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Brooklyn Immunotherapeuti position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Brooklyn Immunotherapeuti will appreciate offsetting losses from the drop in the long position's value.

Moving together with Brooklyn Immunotherapeuti

+0.64MMM3M Company Earnings Call  In Three WeeksPairCorr
+0.91INTCIntel Corp TrendingPairCorr
The ability to find closely correlated positions to Brooklyn Immunotherapeuti could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Brooklyn Immunotherapeuti when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Brooklyn Immunotherapeuti - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Brooklyn Immunotherapeutics to buy it.
The correlation of Brooklyn Immunotherapeuti is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Brooklyn Immunotherapeuti moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Brooklyn Immunotherapeuti moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Brooklyn Immunotherapeuti can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Brooklyn Immunotherapeuti Piotroski F Score and Brooklyn Immunotherapeuti Altman Z Score analysis. You can also try Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Complementary Tools for analysis

When running Brooklyn Immunotherapeuti price analysis, check to measure Brooklyn Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brooklyn Immunotherapeuti is operating at the current time. Most of Brooklyn Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of Brooklyn Immunotherapeuti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brooklyn Immunotherapeuti's price. Additionally, you may evaluate how the addition of Brooklyn Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Is Brooklyn Immunotherapeuti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brooklyn Immunotherapeuti. If investors know Brooklyn will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brooklyn Immunotherapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Brooklyn Immunotherapeuti is measured differently than its book value, which is the value of Brooklyn that is recorded on the company's balance sheet. Investors also form their own opinion of Brooklyn Immunotherapeuti's value that differs from its market value or its book value, called intrinsic value, which is Brooklyn Immunotherapeuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brooklyn Immunotherapeuti's market value can be influenced by many factors that don't directly affect Brooklyn Immunotherapeuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brooklyn Immunotherapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine Brooklyn Immunotherapeuti value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brooklyn Immunotherapeuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.